Menu

Power Up! CRISPRi & CRISPRa Tools for Genome-Wide Screening

Horizon Discovery is leveraging these technologies to address novel research questions and deliver insights into essential gene function, hypomorphic expression, and gene dominance.

Aug 2, 2017
The Scientist Creative Services Team

Power Up! CRISPRi & CRISPRa Tools for Genome-Wide Screening from thescientistllc on Vimeo.

Forward genetic screening with CRISPR-Cas9 has created remarkable new opportunities for biological discovery. The power of complete gene knockout in a pooled screening platform has delivered novel target ID, tackled complex mechanism of action, and driven the design of efficient and economical patient stratification for clinical studies. Using transcriptional regulation with catalytically-dead Cas9 (dCas9), both loss-of-function studies (CRISPR interference, CRISPRi) and gain-of-function studies (CRISPR activation, or CRISPRa) are now possible at a genome-wide level. Horizon Discovery is leveraging these technologies to address novel research questions and deliver insights into essential gene function, hypomorphic expression, and gene dominance. In this webinar we will introduce these new powerful tools and share our screening datasets. Attendees can interact with our expert speaker during the live webinar, asking questions and discussing their experiences.

Topics to be covered:

  • Introduction to CRISPRi and CRISPRa and their use in functional genomic screening
  • How to use CRISPRi/a screening for target ID and validation, understanding drug MOA and patient stratification
  • Screen design and how to evaluate success of your screening program
  • Example screening datasets and how to analyse and interpret the data

View the Video Now

Meet the Speaker:

Benedict Cross, PhD
Functional Genomic Screening Lead
Horizon Discovery

 

 

 

 

 

 

 

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!